GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » EV-to-EBIT

Oculis Holding AG (FRA:CR5) EV-to-EBIT : -9.06 (As of May. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oculis Holding AG's Enterprise Value is €403.61 Mil. Oculis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-44.57 Mil. Therefore, Oculis Holding AG's EV-to-EBIT for today is -9.06.

The historical rank and industry rank for Oculis Holding AG's EV-to-EBIT or its related term are showing as below:

FRA:CR5' s EV-to-EBIT Range Over the Past 10 Years
Min: -37.38   Med: 0   Max: 0
Current: -9.01

FRA:CR5's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 8.915 vs FRA:CR5: -9.01

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Oculis Holding AG's Enterprise Value for the quarter that ended in Dec. 2023 was €268.12 Mil. Oculis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-44.57 Mil. Oculis Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -16.62%.


Oculis Holding AG EV-to-EBIT Historical Data

The historical data trend for Oculis Holding AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG EV-to-EBIT Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - - -3.03

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -10.45 -6.73 -3.03

Competitive Comparison of Oculis Holding AG's EV-to-EBIT

For the Biotechnology subindustry, Oculis Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oculis Holding AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's EV-to-EBIT falls into.



Oculis Holding AG EV-to-EBIT Calculation

Oculis Holding AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=403.607/-44.567
=-9.06

Oculis Holding AG's current Enterprise Value is €403.61 Mil.
Oculis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-44.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oculis Holding AG  (FRA:CR5) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Oculis Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-44.567/268.123515
=-16.62 %

Oculis Holding AG's Enterprise Value for the quarter that ended in Dec. 2023 was €268.12 Mil.
Oculis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-44.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oculis Holding AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (FRA:CR5) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines